With a minimum daily dose of 500 mg, all finished products using Pacran can make claims such as “helps prevent recurrent urinary tract infections in women," or “used in herbal medicine to help prevent (recurrent) urinary tract infections".
Urinary tract infections (UTIs) are a universal problem, with nearly half of all women suffering from a UTI at some point in their lives, and nearly one in three of those women suffering from recurrent UTIs within one year. Formulators are challenged with selecting the right ingredient for their urinary tract health products.
The new approval reinforces the renown of Pacran, which already has a Health Functional Food Ingredient Certificate in South Korea, allowing all finished products to claim: “can help urinary tract health by inhibiting adherence of harmful bacteria to urinary tract".
“The recent health claim approvals from Canada and South Korea independently validate the strength of the scientific substantiation that we’ve built in support of Pacran," said Dan Souza, senior director of sales and marketing for Naturex-DBS.
Pacran is a 100-percent all-natural full spectrum cranberry ingredient supported by eight efficacy and safety studies. A daily dose of 500 mg of Pacran has been shown to reduce the rate of recurrent UTIs, reduce E. coli - the bacteria responsible for 65 to 85 percent of UTIs –in vivo and deliver E.coli anti-adhesion in ex vivo trials. This evidence drove Pacran’s recent health claim approvals.